Arrow-right Camera
The Spokesman-Review Newspaper

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Partly Cloudy Night 52° Partly Cloudy

Study finds long-acting shot helps women avoid HIV infection

UPDATED: Mon., Nov. 9, 2020

Nurse Nomautanda Siduna, right, talks to a patient July 2 who is HIV-positive inside a gazebo used as a mobile clinic in Ngodwana, South Africa.   (Associated Press)
Nurse Nomautanda Siduna, right, talks to a patient July 2 who is HIV-positive inside a gazebo used as a mobile clinic in Ngodwana, South Africa.  (Associated Press)
By Marilynn Marchione Associated Press

Researchers are stopping a study early after finding that a shot of an experimental medicine every two months worked better than daily pills to help keep women from catching HIV from an infected sex partner.

The news is a boon for AIDS prevention efforts especially in Africa, where the study took place, and where women have few discreet ways of protecting themselves from infection.

Results so far suggest that the drug, cabotegravir, was 89% more effective at preventing HIV infection than Truvada pills.

The results mirror those shared earlier this year from a study testing the shots versus the pills in gay men.

Cabotegravir is being developed by ViiV Healthcare, which is mostly owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited. The study was sponsored by the U.S. National Institutes of Health, the Bill and Melinda Gates Foundation and ViiV. The drugs were provided by ViiV and Gilead Sciences.

“This is a major, major advance,” said Dr. Anthony Fauci, the top infectious disease doctor at the NIH. “I don’t think we can overemphasize the importance of this study.

It promises HIV prevention help to young women, “those who need it the most,” he said.

Young women may be twice as likely as men to get HIV in some areas of the world, according to one study leader, Sinead Delany-Moretlwe of the University of the Witwatersrand in Johannesburg, South Africa.

“They need discreet options … without having to negotiate with their partners” to use measures such as condoms, said Deborah Waterhouse, of ViiV.

The study involved over 3,200 people in seven African countries who were assigned to get either the shots every two months or daily Truvada pills. Independent monitors advised stopping the study after seeing that only 0.21% of women receiving the shots caught the AIDS virus versus 1.79% of women on the pills.

There were more side effects, mostly nausea, with the daily pills.

Cabotegravir’s makers are seeking approval from regulators to sell it for this purpose, and Truvada already is widely used.

“The urgent work now” is to make all prevention medicines affordable and more widely available, said Mitchell Warren, who heads AVAC, formerly known as the AIDS Vaccine Advocacy Coalition, a nonprofit focused on prevention efforts that had no role in the study.

Condoms remain widely recommended because they help prevent a host of sexually spread diseases, not just HIV.

“People need choices for HIV prevention,” and this gives a new option, Warren said in a statement.

The Spokesman-Review Newspaper

Local journalism is essential.

Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.

Active Person

Subscribe to the Coronavirus newsletter

Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.